Salvage therapy with azacitidine for pediatric acute myeloid leukemia with t(16;21)(p11;q22)/FUS‐ERG and early relapse after allogeneic blood stem cell transplantation: A case report

Dai Keino; Takashi Mori; Mizuho Morimoto; Kensuke Kondo; Tetsuya Mori; Akitoshi Kinoshita

doi:10.1002/ccr3.2461

Clinical Case Reports (Nov 2019)

Salvage therapy with azacitidine for pediatric acute myeloid leukemia with t(16;21)(p11;q22)/FUS‐ERG and early relapse after allogeneic blood stem cell transplantation: A case report

Dai Keino,
Takashi Mori,
Mizuho Morimoto,
Kensuke Kondo,
Tetsuya Mori,
Akitoshi Kinoshita

Affiliations

Dai Keino: Department of Pediatrics St. Marianna University School of Medicine Kanagawa Japan
Takashi Mori: Department of Pediatrics St. Marianna University School of Medicine Kanagawa Japan
Mizuho Morimoto: Department of Pediatrics St. Marianna University School of Medicine Kanagawa Japan
Kensuke Kondo: Department of Pediatrics St. Marianna University School of Medicine Kanagawa Japan
Tetsuya Mori: Department of Pediatrics St. Marianna University School of Medicine Kanagawa Japan
Akitoshi Kinoshita: Department of Pediatrics St. Marianna University School of Medicine Kanagawa Japan

DOI: https://doi.org/10.1002/ccr3.2461
Journal volume & issue: Vol. 7, no. 11
pp. 2149 – 2152

Abstract

Read online

Abstract Acute myeloid leukemia (AML) with FUS‐ERG has a poor prognosis regardless of allo‐hematopoietic stem cell transplantation (HSCT). Maintenance therapy such as azacitidine after allo‐HSCT for AML with FUS‐ERG may be clinically meaningful.

Published in Clinical Case Reports

ISSN: 2050-0904 (Online)
Publisher: Wiley
Country of publisher: United Kingdom
LCC subjects: Medicine: Medicine (General)
Website: https://onlinelibrary.wiley.com/journal/20500904

About the journal

Abstract

Keywords